UK markets open in 3 hours 42 minutes

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
43.72+0.09 (+0.21%)
At close: 04:00PM EDT
43.72 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close43.63
Open43.41
Bid43.64 x 400
Ask43.95 x 100
Day's range42.60 - 44.31
52-week range19.81 - 52.03
Volume901,846
Avg. volume648,259
Market cap2.566B
Beta (5Y monthly)1.10
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

    Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metast

  • Globe Newswire

    Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

    Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trialZeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDACBased on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRU

  • GlobeNewswire

    Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

    If approved, Zeno will be the first targeted therapy for NRG1+ cancerUTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zen